Absci Corporation (ABSI)
NASDAQ: ABSI · Real-Time Price · USD
2.830
-0.100 (-3.41%)
At close: Aug 18, 2025, 4:00 PM
2.849
+0.019 (0.68%)
After-hours: Aug 18, 2025, 7:59 PM EDT
Company Description
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.
The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics.
Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin for joint research and development activities.
The company was founded in 2011 and is headquartered in Vancouver, Washington.
Absci Corporation
| Country | United States |
| Founded | 2011 |
| IPO Date | Jul 22, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 157 |
| CEO | Sean McClain |
Contact Details
Address: 18105 SE Mill Plain Boulevard Vancouver, Washington 98683 United States | |
| Phone | 360 949 1041 |
| Website | absci.com |
Stock Details
| Ticker Symbol | ABSI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001672688 |
| CUSIP Number | 00091E109 |
| ISIN Number | US00091E1091 |
| Employer ID | 85-3383487 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Sean McClain | Founder, Chief Executive Officer, President and Director |
| Dr. Zachariah Jonasson Ph.D. | Chief Business Officer and Chief Financial Officer |
| Dr. Andreas Busch Ph.D. | Chief Innovation Officer and Member of Scientific Advisory Board |
| Alexander Khan CPA | Vice President of Finance and Head of Investor Relations |
| Shelby Walker J.D. | Chief Legal Officer |
| Karin Wierinck | Chief People Officer |
| Melissa Patterson Ph.D. | Chief of Staff |
| Wen Sha | Chief of Staff |
| Dr. Christine Lemke D.V.M., M.B.A., Ph.D. | Senior Vice President of Portfolio and Growth Strategy |
| Dr. Christian Stegmann M.B.A., Ph.D. | Senior Vice President of Drug Creation |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | 8-K/A | [Amend] Current report |
| Aug 12, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |
| Jul 29, 2025 | SCHEDULE 13G | Filing |
| Jul 25, 2025 | 424B5 | Filing |
| Jul 25, 2025 | 8-K | Current Report |
| Jul 24, 2025 | 424B5 | Filing |
| Jul 16, 2025 | SCHEDULE 13G/A | Filing |
| Jul 8, 2025 | 8-K | Current Report |